Entera Bio Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $42.0K | $181.0K | $0 | $134.0K | $571.0K | $365.0K |
| Cost of Revenue | $42.0K | $172.0K | $0 | $101.0K | $373.0K | $300.0K |
| Gross Profit | $0 | $9.0K | $0 | $33.0K | $198.0K | $65.0K |
| Gross Margin | 0.0% | 5.0% | — | 24.6% | 34.7% | 17.8% |
| Operating Expenses | ||||||
| Research & Development | $6.0M | $4.5M | $4.5M | $5.8M | $6.8M | $6.4M |
| SG&A Expense | $398.0K | $340.0K | $4.4M | $7.3M | $5.7M | $4.9M |
| Operating Income | $-11.5M | $-9.6M | $-8.9M | $-13.0M | $-12.2M | $-11.2M |
| Operating Margin | -27,450.0% | -5,295.6% | — | -9,714.2% | -2,139.6% | -3,059.7% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-11.4M | $-9.5M | $-8.9M | $-12.9M | $-12.2M | $-11.2M |
| Income Tax Expense | $0 | $14.0K | $29.0K | $137.0K | $-59.0K | $20.0K |
| Net Income | $-11.4M | $-9.5M | $-8.9M | $-13.1M | $-12.2M | $-11.2M |
| Net Margin | -27,235.7% | -5,271.3% | — | -9,754.5% | -2,134.3% | -3,072.9% |
| EPS (Basic) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 | $0.67 |
| EPS (Diluted) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 | $0.67 |
| Shares Outstanding (Basic) | 46.2M | 37.7M | 29.0M | 28.8M | 26.1M | 21.1M |
| Shares Outstanding (Diluted) | 46.2M | 37.7M | 29.0M | 28.8M | 26.1M | 21.1M |
| Dividends Per Share | — | — | — | — | — | — |